NCT03195049 (COET) is a NA clinical trial of blood group,complete blood count in Kernicterus, sponsored by Assiut University.

Who is sponsoring NCT03195049?

NCT03195049 is sponsored by Assiut University.

What drugs are being tested in NCT03195049?

Interventions in NCT03195049: blood group,complete blood count.

What condition does NCT03195049 study?

NCT03195049 studies Kernicterus.

Is NCT03195049 still recruiting?

NCT03195049 is currently status unknown. Last updated 22 June 2017.

Last reviewed 2017-06-22 · How we verify

NCT03195049: COET

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Complications of Exchange Transfusion in Neonates

Status unknown NA Last updated 22 June 2017

What this trial tests

NA trial testing blood group,complete blood count in Kernicterus in 50 participants. Status unknown.

Timeline

15 April 2018

Primary endpoint
15 April 2019

15 September 2019

Quick facts

Lead sponsor	Assiut University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	15 April 2018
Primary completion	15 April 2019
Estimated completion	15 September 2019

Drugs / interventions tested

blood group,complete blood count

Conditions studied

Kernicterus — all drugs for Kernicterus →

Sponsor

Assiut University

Who can join

Adults 1 Day to 4 Weeks, any sex, with Kernicterus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Exchange transfusion is effective and considered to be safe procedure ; however, it is not without risks. Complications have been reported and mortality rates vary from 0.5 to 3.3%. therefore ,the current recommendation for performing exchange transfusion are based on balance between the risks of encephalopathy and complications related to the procedure .

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03195049 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 22 June 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03195049.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing